CSHL 2025 Advances in Brain Tumor Research & Therapy Conference - Recent years have produced transformative discoveries that have revealed the mechanisms behind the development and progression of brain cancer, both from the perspective of the tumor cell and the host response. The goal of this conference will be to bring together basic and clinical researchers to discuss and debate cutting-edge concepts and breakthroughs in the brain tumor field to help develop innovative, mechanism-based diagnostic, prognostic, and therapeutic approaches that will significantly advance the care of brain tumor patients. The meeting will cover both pediatric and adult brain tumors and will focus on (1) deciphering the mechanisms that control normal brain development and how aberrations of such mechanisms produce disease, (2) studying how alterations in molecular pathways (including genetic and epigenetic events) result in clinical phenotypes, (3) understanding how the brain and immune microenvironment affect tumor initiation and growth, and (4) investigating how such knowledge can be translated into improved patient care.. The program will include one keynote address, six oral sessions, one poster session, and ample opportunities for social interactions including career lunches and other networking opportunities. An important feature of the meeting will be bringing together eminent leaders and early stage and early established investigators in the field, in order to build relationships and provide mentoring and networking opportunities to cement the commitment of the new generation of scientists and clinicians to the field and provide them with the tools to make a difference in the lives of brain tumor patients, and create opportunities to explore potential collaborations. The precise scope of the individual sessions will be decided on the basis of the openly submitted abstracts. It is anticipated that the meeting will provide unique opportunities for the exchange of data and ideas by both junior and senior investigators in different areas of research as they apply to our fundamental understanding of how brain tumors arise and become malignant, offering improved opportunities for therapeutic advances. We anticipate the attendance will be modest with about 200-250 scientists from laboratories around the world. The meeting will be extensively evaluated by participants, and their ideas and opinions will be discussed in an open session and will be taken into consideration in planning for subsequent years.
